ReviewClinical hematology international2023

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?

Ahmed H Al Sharie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.